Attovia Therapeutics, Inc. (ATTO) Ownership
ATTO ownership summary
as of October 18, 2026- Institutions
- 37.9% of shares outstanding
- Insiders
- 9.05% of shares outstanding
- Shares outstanding
- 45.7M
- Float
- 26.3M shares available to trade
- Short interest
- — 1.6M shares short
- Days to cover
- 4.24 short interest up 98.5% vs prior month
- Institutions 37.94%
- Insiders 9.05%
- Other investors 53.01%
ATTO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Select Biotechnology | 1.54% | 700K | $9.6M | +700,000 (0.0%) | August 31, 2026 |
| 2 | Schwab US Small-Cap ETF™ | 0.20% | 89K | $1.2M | +54 (+0.1%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 0.16% | 74K | $1.0M | +73,973 (0.0%) | August 31, 2026 |
| 4 | Fidelity Nasdaq Composite Index | 0.09% | 42K | $581,191 | +42,330 (0.0%) | August 31, 2026 |
| 5 | Strategic Advisers U.S. Total Stock | 0.08% | 35K | $480,550 | +35,000 (0.0%) | August 31, 2026 |
| 6 | Vanguard Russell 2000 ETF | 0.04% | 18K | $244,421 | +17,802 (0.0%) | August 31, 2026 |
| 7 | Wellington Global Hlthcr Eq USD G Ac | 0.04% | 18K | $244,394 | +17,800 (0.0%) | August 31, 2026 |
| 8 | Hartford Healthcare Y | 0.03% | 12K | $170,252 | +12,400 (0.0%) | August 31, 2026 |
| 9 | Schwab US Broad Market ETF™ | 0.02% | 11K | $154,710 | — | September 30, 2026 |
| 10 | Wellington US Research Eq USD S AccUnH | 0.02% | 11K | $146,911 | +10,700 (0.0%) | August 31, 2026 |
| 11 | Global Atlantic Wellington RsrchMgdRskII | <0.01% | 2,100 | $28,833 | +2,100 (0.0%) | August 31, 2026 |
| 12 | Hartford Healthcare HLS IA | <0.01% | 1,800 | $24,714 | +1,800 (0.0%) | August 31, 2026 |
| 13 | Vanguard Russell 2000 Growth ETF | <0.01% | 1,782 | $24,467 | +1,782 (0.0%) | August 31, 2026 |
| 14 | GlobalAccess US Sm & Md Cp Eq M Dis GBP | <0.01% | 1,466 | $20,128 | — | September 30, 2026 |
| 15 | Vanguard Balanced Index Inv | <0.01% | 1,254 | $17,217 | +1,254 (0.0%) | August 31, 2026 |
| 16 | Vanguard MStar Inst Ttl StkMktIdxInstlPl | <0.01% | 1,114 | $15,295 | +1,114 (0.0%) | August 31, 2026 |
| 17 | Vanguard U.S. Eq Idx £ Acc | <0.01% | 891 | $12,233 | +891 (0.0%) | August 31, 2026 |
| 18 | Interfund Equity Team USA I | <0.01% | 782 | $10,737 | +782 (0.0%) | August 31, 2026 |
| 19 | Vanguard Russell 2000 Value ETF | <0.01% | 648 | $8,897 | +648 (0.0%) | August 31, 2026 |
| 20 | Vanguard Russell 3000 ETF | <0.01% | 263 | $3,611 | +263 (0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns ATTO
Institutional investors own 37.9% of Attovia Therapeutics's shares and insiders 9.05%.
Related: ATTO analyst forecast, ATTO key metrics. See the ATTO stock overview for the latest quote and news.
ATTO ownership FAQ
What percentage of Attovia Therapeutics is owned by institutions?
Institutions hold 37.9% of Attovia Therapeutics's shares outstanding; insiders hold 9.05%.
Which funds own Attovia Therapeutics?
The largest fund holders of Attovia Therapeutics are Fidelity Select Biotechnology (1.54%), Schwab US Small-Cap ETF™ (0.20%), Vanguard MStar Total Stk Mkt Idx Invest (0.16%), Fidelity Nasdaq Composite Index (0.09%), Strategic Advisers U.S. Total Stock (0.08%).
How many shares of Attovia Therapeutics are outstanding?
Attovia Therapeutics has 45.7M shares outstanding, of which 26.3M are in the public float.